Table 1.
Baseline clinical characteristics of patients responding and not responding to anti-TNFα treatment
| Responding group (n = 13) |
Non-responding group (n = 11) |
T test p value | |
|---|---|---|---|
| Demographic factors | |||
| Age [years] | 31.3 ± 5.8 | 44.4 ± 11.2 | 0.001 |
| Sex | M 10 (76.9%) F 3 (23.1%) |
M 9 (81.8%) F 2 (18.2%) |
0.8 |
| BMI—baseline | 28.3 ± 3.5 | 26.7 ± 3.6 | 0.3 |
| Body mass—baseline [kg] | 83.9 ± 11.0 | 79.6 ± 15.4 | 0.4 |
| Current smoking | 4 (30.8%) | 3 (27.3%) | 0.9 |
| Disease-related factors | |||
| Duration of the disease [years] | 6.4 ± 4.4 | 7.7 ± 8.5 | 0.7 |
| Age at diagnosis | 24.9 ± 7.6 | 36.6 ± 11.1 | 0.006 |
| HLA-B27 | 11 (84.6%) | 10 (90.9%) | 0.6 |
| BASDAI | 6.9 ± 1.1 | 7.4 ± 0.9 | 0.2 |
| ASDAS-CRP | 4.1 ± 0.7 | 4.0 ± 0.6 | 0.6 |
| CRP [mg/l] | 21.0 ± 18.3 | 16.8 ± 17.8 | 0.3 |
| CRP > 10 mg/l | 10 (76.9%) | 5 (45.5%) | 0.1 |
| VAS pain | 71.2 ± 14.7 | 66.3 ± 10.1 | 0.4 |
| Back paina | 8.0 (7.0–8.0) | 8.0 (7.5–8.0) | 0.3 |
| Peripheral arthritisa | 7.0 (4.0–7.0) | 8.0 (7.0–8.0) | 0.04 |
| Morning stiffnessa | 7.0 (6.0–9.0) | 7.0 (4.0–8.5) | 0.6 |
| Drugs | |||
| Anti-TNFα | 0.9 | ||
| • Adalimumab • Etanercept • Infliximab |
4 (30.8%) 7 (53.8%) 2 (15.4%) |
3 (27.3%) 7 (63.6%) 1 (9.1%) |
|
| csDMARDs total | 4 (30.8%) | 5 (45.5%) | 0.5 |
| • Methotrexate • Sulfasalazine |
2 (15.4%) 2 (15.4%) |
2 (18.2%) 3 (27.3%) |
0.7 |
Sex, current smoking, HLA-B27, CRP > 10 mg/l, and drugs are shown as numbers of patients, others as mean ± SD
aFor numeric data, such as back pain, peripheral arthritis, and morning stiffness, the Mann-Whitney U test was performed. Data are shown as median and IQR